Massive breakthrough as new pancreatic cancer treatment can make tumors disappear: Weve never seen such a thing

A pill made to treat one of the deadliest cancers was already setting high expectations after its approval in August.But when used in combination with chemo, it could revolutionize treatment, new data suggests.Clinical trials show the combination is not only stopping pancreatic cancer tumors from growing and spreading — it can eliminate them entirely.“This is the closest to cure,” said oncologist Dr.

Wungki Park, when presenting the findings.“We’ve never seen such a thing.”AdvertisementPrevious research on the drug, daraxonrasib (sold as Rasonque), showed incredible promise.

The drug alone was shown to double survival time for pancreatic cancer, a total of 13.2 months up from 6.7 months.Now, scientists are seeing how daraxonrasib works with chemo.

In clinical trials, this combination caused a vast majority of tumors to stop growing, and some shrank so much they became undetectable.The results are a “a massive, massive breakthrough” in the fight against the third-deadliest cancer, according to Dr.Wungki Park, an oncologist at Memorial Sloan Kettering, who presented the findings.AdvertisementThe study is part of a phase 1/2 clinical trial combining daraxonrasib with gemcitabine and nab-paclitaxel, two chemotherapy drugs, to treat pancreatic cancer that has metastasized, or spread to other parts of the body (stage 4).When using both therapies, nine in 10 patients had tumors shrink or remain stable, while three in five patients saw significant tumor shrinkage or disappearance.About 8.2% (one in 12) patients had no detectable cancer at the end of the study.

More than 76% of participants survived past one year on the treatment.Park noted the findings were significant because this study had a median follow up of 18.3 months, which is much longer than that of previous research.This means we now have a better idea of how long patients benefit from the treatment, and how long tumors stay shrunk.Advertisement“With longer follow-up and a larger patient p...

Read More 
PaprClips
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by PaprClips.
Publisher: New York Post

Recent Articles